Skip to main content

Table 3 Changes in parameters of glycemic control

From: Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study

Parameters

Dapagliflozin group

Metformin group

P value

HbA1c (%)

 Baseline

6.8 ± 0.5 (37)

6.9 ± 0.5 (37)

0.39

 Week 16

6.5 ± 0.5 (37)

6.5 ± 0.6 (37)

0.76

 Change

−0.2 ± 0.4 (37)

−0.4 ± 0.3 (37)

0.09

 P value within group

0.001

<0.001

 

HbA1c (mmol/mol)

 Baseline

50.3 ± 5.5 (37)

51.4 ± 5.7 (37)

0.39

 Week 16

48.0 ± 5.4 (37)

47.5 ± 6.2 (37)

0.76

 Change

−2.4 ± 4.2 (37)

−3.9 ± 3.5 (37)

0.09

 P value within group

0.001

<0.001

 

Fasting plasma glucose (mg/dL)

 Baseline

133.5 ± 27.1 (37)

139.6 ± 20.2 (37)

0.28

 Week 16

122.5 ± 19.5 (37)

125.2 ± 20.0 (37)

0.56

 Change

−11.0 ± 20.2 (37)

−14.4 ± 16.9 (37)

0.44

 P value within group

0.002

<0.001

 

C-peptide (ng/mL)

 Baseline

2.1 ± 0.8 (37)

2.3 ± 1.1 (37)

0.34

 Week 16

2.0 ± 0.8 (37)

2.1 ± 1.0 (37)

0.65

 Change

−0.1 ± 0.5 (37)

−0.2 ± 0.5 (37)

0.29

 P value within group

0.27

0.007

 

Insulin (μIU/mL)

 Baseline

8.9 ± 5.5 (37)

10.3 ± 7.5 (37)

0.38

 Week 16

7.3 ± 4.4 (37)

9.2 ± 7.4 (37)

0.20

 Change

−1.6 ± 3.7 (37)

−1.1 ± 3.8 (37)

0.58

 P value within group

0.012

0.08

 

Glucagon (pg/mL)

 Baseline

164.6 ± 33.5 (37)

171.6 ± 42.4 (37)

0.43

 Week 16

152.9 ± 24.5 (37)

159.3 ± 36.8 (37)

0.39

 Change

−11.7 ± 31.2 (37)

−12.3 ± 31.6 (37)

0.93

 P value within group

0.029

0.023

 

HOMA-IR

 Baseline

3.1 ± 2.4 (37)

3.7 ± 3.2 (37)

0.34

 Week 16

2.3 ± 1.5 (37)

3.0 ± 3.0 (37)

0.16

 Change

−0.8 ± 1.9 (37)

−0.7 ± 1.5 (37)

0.73

 P value within group

0.010

0.009

 
  1. Data are presented as mean ± standard deviation (n). P values show results for comparisons between groups by t test. P values within groups are results of paired t test
  2. HOMA-IR homeostatic model assessment of insulin resistance. See Table 1 for other abbreviations